Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | HTT | P42858 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 7/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.68 |
| ▸ | RAF1 | P04049 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251103 | 0.92 | MAPT (0.71) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4258370 | 0.87 | MAPT (0.71) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4253151 | 0.87 | MAPT (0.71) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4257494 | 0.87 | MAPT (0.78) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4257098 | 0.87 | MAPT (0.80) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4250821 | 0.87 | MAPT (0.71) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4253921 | 0.84 | MAPT (0.68) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4255526 | 0.84 | MAPT (0.76) | MAPTKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4251609 | 0.83 | MAPT (0.74) | MAPTKMT2AMEN1HTTCYP3A4 | |
| SCHEMBL4250981 | 0.82 | MAPT (0.74) | MAPTKMT2AMEN1HTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MAPT 759/4885KMT2A 632/4885MEN1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.